Stock Track | Avadel Pharmaceuticals Plummets 29% in Pre-market as Disappointing 2025 Revenue Outlook Weighs

Stock Track

2025/01/10

Shares of Avadel Pharmaceuticals plc (AVDL) plummeted 29% in the pre-market session on Friday, following the company's disappointing revenue forecast for 2025. The biopharmaceutical company, which specializes in developing drugs for central nervous system disorders, released its 2025 revenue guidance late on Wednesday, projecting revenue in the range of $240 million to $260 million.

This outlook fell short of analysts' average estimate of $267.6 million, according to data from LSEG. The disappointing guidance has led several analysts to revise their price targets for the stock, with HC Wainwright and Piper Sandler lowering their targets to $21 and $13, respectively.

Analysts cited concerns over a slower-than-expected ramp-up in sales of Avadel's sleep disorder drug Lumryz as a key factor behind the muted 2025 guidance. The company's shares have already faced significant pressure over the past year, declining by around 32% leading up to Friday's pre-market slump.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1108863130"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1108863130\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1108863130?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-10 22:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108863130","market":"hk","top_or_hot":-1,"title":"Stock Track | Avadel Pharmaceuticals Plummets 29% in Pre-market as Disappointing 2025 Revenue Outlook Weighs","media":"Stock Track","content":"<p>Shares of Avadel Pharmaceuticals plc (AVDL) plummeted 29% in the pre-market session on Friday, following the company's disappointing revenue forecast for 2025. The biopharmaceutical company, which specializes in developing drugs for central nervous system disorders, released its 2025 revenue guidance late on Wednesday, projecting revenue in the range of $240 million to $260 million.</p>\n\n<p>This outlook fell short of analysts' average estimate of $267.6 million, according to data from LSEG. The disappointing guidance has led several analysts to revise their price targets for the stock, with HC Wainwright and Piper Sandler lowering their targets to $21 and $13, respectively.</p>\n\n<p>Analysts cited concerns over a slower-than-expected ramp-up in sales of Avadel's sleep disorder drug Lumryz as a key factor behind the muted 2025 guidance. The company's shares have already faced significant pressure over the past year, declining by around 32% leading up to Friday's pre-market slump.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Avadel Pharmaceuticals Plummets 29% in Pre-market as Disappointing 2025 Revenue Outlook Weighs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Avadel Pharmaceuticals Plummets 29% in Pre-market as Disappointing 2025 Revenue Outlook Weighs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-01-10 22:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Avadel Pharmaceuticals plc (AVDL) plummeted 29% in the pre-market session on Friday, following the company's disappointing revenue forecast for 2025. The biopharmaceutical company, which specializes in developing drugs for central nervous system disorders, released its 2025 revenue guidance late on Wednesday, projecting revenue in the range of $240 million to $260 million.</p>\n\n<p>This outlook fell short of analysts' average estimate of $267.6 million, according to data from LSEG. The disappointing guidance has led several analysts to revise their price targets for the stock, with HC Wainwright and Piper Sandler lowering their targets to $21 and $13, respectively.</p>\n\n<p>Analysts cited concerns over a slower-than-expected ramp-up in sales of Avadel's sleep disorder drug Lumryz as a key factor behind the muted 2025 guidance. The company's shares have already faced significant pressure over the past year, declining by around 32% leading up to Friday's pre-market slump.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AVDL","symbol_name":"Avadel Pharmaceuticals plc","start_time":0,"source_url":"","article_id":"1108863130","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108863130","pubTimestamp":1736519984,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Avadel Pharmaceuticals plc  plummeted 29% in the pre-market session on Friday, following the company's disappointing revenue forecast for 2025. The biopharmaceutical company, which specializes in developing drugs for central nervous system disorders, released its 2025 revenue guidance late on Wednesday, projecting revenue in the range of $240 million to $260 million.This outlook fell short of analysts' average estimate of $267.6 million, according to data from LSEG. The disappointing g","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AVDL":"Avadel Pharmaceuticals plc"},"translate_title":"由于2025年收入前景令人失望，Avadel Pharmaceuticals盘前暴跌29%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AVDL":1},"content_text":"Shares of Avadel Pharmaceuticals plc (AVDL) plummeted 29% in the pre-market session on Friday, following the company's disappointing revenue forecast for 2025. The biopharmaceutical company, which specializes in developing drugs for central nervous system disorders, released its 2025 revenue guidance late on Wednesday, projecting revenue in the range of $240 million to $260 million.\nThis outlook fell short of analysts' average estimate of $267.6 million, according to data from LSEG. The disappointing guidance has led several analysts to revise their price targets for the stock, with HC Wainwright and Piper Sandler lowering their targets to $21 and $13, respectively.\nAnalysts cited concerns over a slower-than-expected ramp-up in sales of Avadel's sleep disorder drug Lumryz as a key factor behind the muted 2025 guidance. The company's shares have already faced significant pressure over the past year, declining by around 32% leading up to Friday's pre-market slump.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}